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Abstract In this work we demonstrate that transcription of the 
human prolactin gene is inhibited by the immunosuppressants 
FK506 (ICso = 25 nM), cyclosporin A (IC5o = 190 nM) and ra- 
pamycin (ICso = 25 nM). Whereas the effect of FK506 and cy- 
closporin A is specific for prolactin gene transcription, rapamycin 
has a more general effect on transcription and/or translation in 
pituitary cdls. In view of recent work demonstrating the immu- 
noactivating role of prolactin, these results suggest hat inhibition 
of prolactin gene expression in the pituitary may contribute to the 
mechanism of action of immunosuppressants. 
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1. Introduction 
Recently the mechanism of action of the widely used im- 
munosuppressant drug cyclosporin A was elucidated [1-3]. Cy- 
closporin A enters T-lymphocytes where it associates with an 
intracellular receptor termed cyclophilin. The complex between 
cyclosporin A and cyclophilin, but not the individual compo- 
nents, is a potent inhibitor of the Ca2+-dependent protein phos- 
phatase calcineurin [1,2]. Inhibition of calcineurin leads to aber- 
rant phosphorylation f transcription factors and this prevents 
transcription of the interleukin-2 gene, an essential step in T- 
lymphocyte activation. The novel immunosuppressant FK506 
acts in a very similar way since the complex between FK506 and 
its intracellular receptor (FKBP12) is a potent inhibitor of 
calcineurin [1-3]. 
The immunosuppressant rapamycin also associates with 
FKBP12, but this complex does not affect calcineurin activity. 
The rapamycin-FKBP12 complex inhibits the signaling path- 
way distal of the interleukin-2 receptor, most likely via binding 
to a protein termed FRAP [4]. 
Prolactin is an important regulator of the immune system 
(reviewed in [5]) and appears to have a non-specific immuno- 
activating function. Prolactin is mitogenic for T-lymphocytes 
[6]. Administration of antisera to prolactin affects the develop- 
ment of T-lymphocytes in the thymus and the spleen [7]. 
T-lymphocytes express both prolactin and prolactin receptors 
[8]. In view of this immunoregulatory ole of prolactin we 
decided to investigate whether immunosuppressants could in- 
fluence pituitary prolactin gene expression. 
*Corresponding author. Fax: (32) (41) 562 968. 
Abbreviations." CAT, choramphenicol acetyltransferase; hPRL, human 
prolactin; TK, thymidine kinase. 
2. Experimental 
2.1. Materials 
FK506 and rapamycin were kind gifts of Dr. K. Murato (Fujisawa 
GmbH) and Dr. L. Faucette (Smith-Kline Beecham), respectively. Cy- 
closporin A was from Sandoz. Plasmids containing the CAT reporter 
gene linked either to the hPRL promoter or the TK promoter are 
described in [9]. 
2.2. Cell culture and transfection 
GH3 rat pituitary tumor cells were cultured and transfected by elec- 
troporation as described [9], except hat an Easyject apparatus (Euro- 
gentec/Equibio, Seraing, Belgium) was used. Briefly, 10 7 cells were 
gently mixed with 20/.tg plamid DNA and electroporated with a single 
pulse of 1500 pF and 270 V. Cells were incubated for 16 h, then 
harvested and processed for CAT assay as described [9,10]. 
Toxicity of the various drugs was tested by counting Trypan blue- 
excluding cells after an overnight incubation of 0.25 x 106 cells with the 
indicated concentrations of the drug. Results are expressed as 
means + S.E.M. Illustrated results are the mean of 2 experiments each 
performed in triplicate. 
3. Results 
3.1. Immunosuppressants inhibit human prolactin gene 
expression 
Human prolactin (hPRL) gene expression in the pituitary is 
tightly controlled via transcription factors that bind to the 
cis-acting elements present in the promoter egion of the gene. 
We showed previously [9,11] that a CAT reporter gene fused 
to the promoter of the human prolactin gene is a reliable model 
to study prolactin gene expression. In order to study the effect 
of immunosuppressants on transcription of the hPRL gene, we 
transfected rat pituitary tumor cells (GH3) with a construct 
containing 3500 bp of the hPRL promoter linked to a CAT 
reporter gene. In the experiment shown in Fig. 1A, increasing 
concentrations of FK506 progressively inhibited hPRL3500- 
CAT transient expression up to 75% (IC50 = 25 nM). Expres- 
sion of a control TKCAT vector, carrying the neutral promoter 
of the Herpes virus thymidine kinase gene linked to a CAT 
reporter gene, was not affected by FK506. Addition of cy- 
closporin A (Fig. 1B) caused a less pronounced inhibition of 
hPRL3500CAT expression (IC50 = 190 nM) while it did not 
affect the response of the TKCAT construct. Addition of ra- 
pamycin (Fig. 1C) led to the inhibition of hPRL3500CAT ex- 
pression with an IC5o similar to that of FK506. Rapamycin 
caused, however, a similar inhibitory effect on TKCAT expres- 
sion. Moreover, we found that rapamycin (1/.tM) inhibits (to 
51 + 9%) expression of a fl-galactosidase r porter gene linked 
to a cytomegalovirus promoter/enhancer (not shown), indicat- 
ing a more general effect on transcription or translation i  our 
system. GH 3 cell viability was not affected by addition of 
FK506, cyclosporin A or rapamycin in the concentration range 
used in Fig. 1. 
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Fig. 1. Immunosuppressants inhibit hPRL-CAT transient expression. 
GH 3 pituitary tumor cells were transfected with the hPRL3500CAT 
construct (e) or with TKCAT (©). 2 h after transfection the indicated 
concentrations of FK506 (panel A), cyclosporin A (panel B) or rapamy-  
c in  (panel C) were added. Toxicity of the compounds was tested in a 
Trypan blue exclusion assay (/% 
3.2. The proximal hPRL promoter & sufficient o mediate the 
effects of  FK506 
To locate more precisely on the hPRL promoter the cis- 
elements which mediate its inhibition by immunosuppressants, 
we transfected GH 3 cells with a series of hPRLCAT deletion 
mutants (containing from 4700 bp to only 250 bp of the hPRL 
promoter) and monitored their transient expression in the pres- 
ence or absence of 1 pM FK506. Fig. 2 shows that all these 
constructs responded similarly to the drug while the TKCAT 
control did not respond. This implies that the inhibitory effect 
of FK506 is mediated by the proximal 250 bp of the hPRL 
promoter which contains two types of regulatory elements: 
binding sites for the pituitary-specific transcription factor Pit-1, 
and the region extending from -115 to -85 bp named sequence 
A [9,12,13]. Since CAT expression driven by hPRL promoter 
constructs smaller than 250 bp is very low, it is difficult to 
further dissect the hPRL promoter when studying inhibitory 
effects. 
3.3. Immunosuppressants do not affect induction of hPRL gene 
expression by cAMP 
We showed previously that a small region of the proximal 
promoter (-164 to -34) of the hPRL gene can confer sensitivity 
to cAMP when fused to a cAMP-insensitive TKCAT construct 
[9]. Since the basal expression of this construct is driven by the 
TK promoter it is insensitive toFK506. Expression of this -164 
to -34 hPRL-TKCAT construct was stimulated 15.9 fold by 
the addition of cAMP. This stimulation is not significantly 
altered (14.8 + 1.3 fold stimulation) in the presence of 1 pM 
FK506 (not shown), indicating that FK506 does not interfere 
with the cAMP signaling pathway in pituitary cells. 
4. Discussion 
The present work shows that expression of the hPRL gene 
is potently inhibited by immunosuppressants in a pharmacol- 
ogical concentration range. In view of the immuno-activating 
role of prolactin [5], this inhibition might contribute to the 
mechanism of action of cyclosporin A, FK506 and rapamycin, 
and thus act complementary to the inhibition of T-lymphocyte 
activation. Interestingly, the glucocorticoid agonist and im- 
munosuppressant dexamethasone was shown previously to in- 
hibit hPRL gene expression 3 fold [14]. 
In analogy to the inhibition of interleukin-2 gene expression 
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Fig. 2. The effect of FK506 is mediated by the proximal hPRL pro- 
moter. GH 3 pituitary tumor cells were transfected with hPRL pro- 
moter-CAT fusion genes containing 4700 bp, 3500 bp, 1750 bp, and 
250 bp of the hPRL promoter as indicated, or with a TKCAT construct. 
2 h after transfection, 1 pM of FK506 was added as indicated. 
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in T-lymphocytes, FK506- and cyclosporin A-induced inhibi- 
tion of hPRL gene expression in the pituitary might be medi- 
ated by calcineurin inhibition. We observe the inhibition also 
with rapamycin, however, and this compound oes not affect 
calcineurin activity [1-3]. The effect of FK506 and cyclosporin 
A is specific for hPRL gene expression whereas rapamycin also 
inhibits transcription or translation of the CAT and fl-galacto- 
sidase reporter. This indicates that rapamycin inhibits hPRL 
gene expression via a different mechanism than FK506 or cy- 
closporin A. 
The expression of the human prolactin gene is regulated by 
various hormones, factors and toxins, such as cAMP, Ca 2+, 
thyroliberin, epidermal growth factor and okadaic acid 
[9,12,13-15]. Most of the known intracellular second messenger 
pathways converge at the level of the proximal promoter, where 
their effects are mediated by two cis-acting elements: binding 
sites for the transcription factor Pit-1 and sequence A (-115 to 
-85). The binding activity of Pit-1 is controlled through phos- 
phorylation/dephosphorylation [16]. The 100 kDa protein bind- 
ing to sequence A [12] and its regulation remain to be further 
characterized. From the present work it appears that the inhib- 
itory effect of immunosuppressants is also mediated via the 
proximal promoter containing both cis-acting elements. 
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